ENDPOINTS

Lilly to pay up to $415M in ALS deal; Actuate’s mid-stage pancreatic cancer data

Plus, news about Atara Biotherapeutics, Immutep, bluebird bio, OSE Immunotherapeutics, Mersana Therapeutics, Innovent, Biomea Fusion and Trailhead Biosystems: Eli Lilly does another ALS deal: The pharma is licensing an IND-ready antibody from Alchemab Therapeutics. Lilly ...

May 6, 2025 - 15:45
 0
Lilly to pay up to $415M in ALS deal; Actuate’s mid-stage pancreatic cancer data
Plus, news about Atara Biotherapeutics, Immutep, bluebird bio, OSE Immunotherapeutics, Mersana Therapeutics, Innovent, Biomea Fusion and Trailhead Biosystems: Eli Lilly does another ALS deal: The pharma is licensing an IND-ready antibody from Alchemab Therapeutics. Lilly ...
Read More

Tags:

Previous Article

Aviation Professionals Call For A New Flight Plan On Emissions

Next Article

Spot the Station Frequently Asked Questions

Related Posts

Amicus grabs Dimerix’s rare kidney disease drug for $30M upfront

Amicus grabs Dimerix’s rare kidney disease drug for $30...

May 1, 2025  0

Merck Q1 earnings: Gardasil sales hit by China market pressure

Merck Q1 earnings: Gardasil sales hit by China market p...

Apr 24, 2025  0

Merck cuts several Phase 2 programs; Vyne’s Phase 1b psoriasis trial put on clinical hold

Merck cuts several Phase 2 programs; Vyne’s Phase 1b ps...

Apr 25, 2025  0